Stephen Hauser reports the ongoing safety data for ocrelizumab in patients with relapsing or primary progressive multiple sclerosis, including preliminary post-marketing experience of a small group of patients with COVID-19 (5:13).
Stephen Hauser reports the ongoing safety data for ocrelizumab in patients with relapsing or primary progressive multiple sclerosis, including preliminary post-marketing experience of a small group of patients with COVID-19 (5:13).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
